Inhibition of Mitochondrial-Associated Protein MAGMAS Resensitizes Chemoresistant Prostate Cancer Cells to Docetaxel
Cancers · 30.04.2025 · 17 (9) · 1535
DOI: 10.3390/cancers17091535 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancers, online erschienen am 30.04.2025. Verfasst von Alfonso M Durán und 15 weiteren Autor:innen. Beteiligte Einrichtung: Center for Health Disparities and Molecular Medicine, Loma Linda University School of Medicine, Loma Linda, CA 92350, USA. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 67 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Institutes of Health (NIH).
Abstract (Originalsprache)
Background/Objectives: Metastatic prostate cancer (PCa) is the leading cause of cancer-related deaths and a major contributor to cancer mortality in men. Most patients with metastatic PCa eventually develop metastatic castration-resistant prostate cancer (mCRPC), characterized by resistance to treatment with androgen-deprivation therapy, and often later the development of resistance to other types of agents. MAGMAS, a 13.8 kDa mitochondrial-associated protein, facilitates the import of nuclear-encoded proteins into the mitochondrial matrix. Overexpression of MAGMAS has been observed in several aggressive cancers, including breast, glioblastoma, and prostate cancer. When overexpressed, MAGMAS acts as a cytoprotective protein by scavenging reactive oxygen species (ROS), maintaining ROS levels that support cell proliferation while avoiding the induction of apoptosis. This study investigates the role of MAGMAS in therapy resistance in PCa cells. Methods/Results: Quantitative immunoblotting revealed that MAGMAS is endogenously upregulated in docetaxel-resistant (DR) PCa cell lines compared to their docetaxel-sensitive parental counterparts. While MAGMAS depletion alone did not affect the survival of DR cells, it significantly sensitized them to docetaxel (DTX), as indicated by a marked reduction in clonogenic potential. Additionally, transient knockdown of MAGMAS in these resistant cells significantly decreased the levels of ABCB1 protein. Consistent with these findings, sub-therapeutic inhibition of MAGMAS using the novel BT#9 inhibitor, in combination with increasing concentrations of DTX, enhanced the sensitivity of DR cells to DTX, as demonstrated by proliferation and clonogenic assays. Lastly, RNA tumor expression predicts overall survival (OS). Conclusions: These results implicate MAGMAS in PCa chemoresistance and suggest that targeting this protein could provide a novel therapeutic strategy for treating DR tumors.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Center for Health Disparities and Molecular Medicine, Loma Linda University School of Medicine, Loma Linda, CA 92350, USA.
- Department of Basic Sciences, Loma Linda University School of Medicine, Loma Linda, CA 92350, USA.
- Cancer Center, Loma Linda University Health, Loma Linda, CA 92354, USA.
- Caris Life Sciences, Phoenix, AZ 85040, USA.
- Department of Pharmaceutical Sciences, School of Pharmacy and Pharmaceutical Sciences, University at Buffalo, Buffalo, NY 14215, USA.
- Highlands Oncology, Rogers, AR 72758, USA.
ORCID-Profile: Kristen Whitley, Carlos A Casiano
Förderung
- National Institutes of Health (NIH)
Zitieren
APA
Durán, A. M., Whitley, K., Santiago, K., Yoo, C., Valdez, G., Cheng, K. W., Ochoa, P., de Semir, D., Xiu, J., Chokkalingam, P., Das, S., Schaefer, E. S., Rowe, S. P., Das, B. C., Casiano, C. A., & Almaguel, F. (2025). Inhibition of Mitochondrial-Associated Protein MAGMAS Resensitizes Chemoresistant Prostate Cancer Cells to Docetaxel. Cancers, 17(9), 1535. https://doi.org/10.3390/cancers17091535
Vancouver
Durán AM, Whitley K, Santiago K, Yoo C, Valdez G, Cheng KW, et al. Inhibition of Mitochondrial-Associated Protein MAGMAS Resensitizes Chemoresistant Prostate Cancer Cells to Docetaxel. Cancers. 2025;17(9):1535. doi:10.3390/cancers17091535
BibTeX
@article{Durn2025,
author = {Durán, Alfonso M and Whitley, Kristen and Santiago, Krystal and Yoo, Christian and Valdez, Giancarlo and Cheng, Kai Wen and Ochoa, Pedro and de Semir, David and Xiu, Joanne and Chokkalingam, Parthiban and Das, Sasmita and Schaefer, Eric S and Rowe, Steven P and Das, Bhaskar C and Casiano, Carlos A and Almaguel, Frankis},
title = {Inhibition of Mitochondrial-Associated Protein MAGMAS Resensitizes Chemoresistant Prostate Cancer Cells to Docetaxel},
journal = {Cancers},
year = {2025},
volume = {17},
number = {9},
pages = {1535},
doi = {10.3390/cancers17091535}
}
EUVIMED